You need to enable JavaScript to run this app.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
AML Types
Signaling pathway mutations
Epigenetic modifier mutations
Origin
Chromosomal aberrations
Nucleophosmin mutations
Tumor suppressor mutations
Spliceosome mutations
Transcription factor mutations
Cohesin mutations
View all Types
Isolda Fernandez
Scientific Advisory Board Member
Isolda Fernandez
Scientific Advisory Board Member
Types
Core binding factor
De novo
FLT3-ITD
IDH1
IDH2
NPM1
Promyelocytic leukemia
Secondary
Interventions
AMG 330
AMV564
Blinatumomab
Enasidenib
Gilteritinib
Ivosidenib
Midostaurin
Nivolumab
Venetoclax
Events
ASH 2017
ASH 2019
EHA 2017
EHA 2018
EHA 2019
NCRI AML Academy 2019
Trials
AML17
E2906
FLUGAZA
All
|
3 Articles
|
4 Videos
|
0 Podcasts